22 September 2015 - “Turing is not a GPhA member and has no relationship with GPhA. No single company and no single product represents the entire generic drug industry which has an undeniable record of patient savings and access. In fact, generic drugs were responsible for $239 billion in health savings in 2013 and $1.46 trillion in savings over the most recent decade. Any inquiries relating to Turing should be directed toward the company itself.

Generic medicines are a critical part of system-wide efforts to hold down healthcare costs. It is important to remember that FDA-approved generic drugs remain significantly more affordable than costly brand drugs while being just as safe and effective.

Recent data shows that the generic cost trend continues to decline. In fact, drug costs are a small portion (approximately 10%) of overall health system costs and generic drugs are an even smaller fraction of that expenditure. Rather than targeting one of the few industries that has demonstrated success saving people billions of dollars, GPhA welcomes a constructive discussion on what can be done to keep prescription drugs affordable while balancing innovation and competition.

For more details, go to: http://www.gphaonline.org/gpha-media/press/statement-by-chip-davis-president-and-ceo-gpha-regarding-generic-drug-costs